Sort   by:  
 Page size 
UnknownResearch hotspots and trends in the field of immune checkpoint inhibitors (ICIs) for cervical cancer: A bibliometric study from 2014 to 2024.
Not available
S-EPMC11959921 | biostudies-literature
UnknownPhase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.
Not available
S-EPMC5321045 | biostudies-literature
UnknownClinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
Not available
S-EPMC5931107 | biostudies-literature
UnknownPhase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.
Not available
S-EPMC12648153 | biostudies-literature
UnknownPhotoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.
Not available
S-EPMC4336708 | biostudies-literature
UnknownConcordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology.
Not available
S-EPMC12929784 | biostudies-literature
UnknownQuantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel.
Not available
S-EPMC7556717 | biostudies-literature
UnknownDual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
Not available
S-EPMC7171918 | biostudies-literature
UnknownA Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC.
Not available
S-EPMC9576893 | biostudies-literature
UnknownRAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Not available
S-EPMC10964523 | biostudies-literature
Sort   by:  
 Page size